NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Summit Therapeutics Inc. (SMMT) Stock Analysis

Summit Therapeutics Inc. (SMMT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SMMT

$17.61

+$0.48 (+2.77%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SMMT with… →

SMMT Key Statistics

As of Sep 4, 2026
Trading
Open
$16.94
Previous Close
$17.13
Day's Range
16.80–17.63
52-Week Range
12.07–29.23
Volume
6.93M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.24
Valuation
Market Cap
$14.04B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.11
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.08B
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
797.75M
1-Year Return
−26.03%
Dividend and dates
Earnings Date
October 19, 2026estimated
Avg Volume
5.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SMMT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.66%
2025−1.99%
2024+583.72%
2023−38.59%
2022+57.99%
2021−42.77%
2020+193.75%
2019+39.13%
2018−89.62%
2017+29.44%
2016 (partial year)+25.33%

As of September 4, 2026.

SMMT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.08B—
2024$0.00−$221.32M—
2023$0.00−$614.93M—
2022$705.00K−$78.78M−11174.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$1.09B−$1.08B—
2024$0.00—−$210.98M−$221.32M—
2023$0.00—−$88.74M−$614.93M—
2022$705.00K—−$63.62M−$78.78M−11174.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SMMT Valuation vs Biotechnology Median

Median of 656 stocks
MetricSMMTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Summit Therapeutics Inc. (SMMT) is capitalised at $14.04B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 265.

Over the past 52 weeks the price has ranged from $12.07 to $29.23. The most recent close on file for SMMT is $17.61, dated September 4, 2026. That is +$0.48 (+2.77%) against the previous close. The latest close sits 45.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $1.08B. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.11.

Across the 4 fiscal years on file, revenue moves from $705.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −1.24. Annualized volatility over the trailing 10 years is 144.68%. Over the trailing twelve months the price has returned −26.03%. Measured over 10 years, that is +10.23% a year compounded.

Growth & Income

The record shows no dividend for SMMT.

2026 is still running; the price is +0.66% year to date. The strongest complete calendar year on file is 2024 at +583.72%; the weakest is 2018 at −89.62%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Summit Therapeutics Inc. (SMMT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Summit Therapeutics Inc. SMMT $14.04B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Summit Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Visit website →